We were delighted to speak with Prof. Erika Petersen (University of Arkansas for Medical Sciences, Little Rock, AR, USA) around the six month results from the SENZA-PDN study.
The abstract entitled: ‘Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy—Six Month Results from a Multicenter Randomized Controlled Trial’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions
- What are the unmet needs in the treatment of patients with painful diabetic neuropathy? (00:13)
- What evidence supports the use of 10 kHz spinal cord stimulation? (1:10)
- Could you tell us a little about the SENZA-PDN study and its findings? (2:24)
- What will be the clinical impact of these findings? (3:46)
- Which patients are likely to benefit most from this treatment? (5:19)
Disclosures: SENZA PDN study is sponsored by Nevro, Inc and registered at Clinicaltrials.gov. Dr Petersen has received research support from Medtronic, Neuros Medical, Nevro Corp, and ReNeuron as well as personal fees from Nevro, Abbott Neuromodulation, Medtronic Neuromodulation, and Neuros Medical.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Reference: Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy. JAMA Neurol. 2021; doi: 10.1001/jamaneurol.2021.0538.
